- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04335409
Pneumonitis After Radiotherapy for Lung Cancer (PARALUC)
Pneumonitis After Radiotherapy for Lung Cancer: A Symptom-Based Scoring System to Identify Patients Developing Radiation Pneumonitis
Major goals of radiotherapy include local disease control and improvement of the patients' prognoses. One possible side effect of radiotherapy for lung cancer is radiation pneumonitis. Severe (grade ≥3) radiation pneumonitis can even be fatal in approximately 2% of the patients. It would be important to identify patients developing radiation pneumonitis and requiring medical treatment early.
In the present study, the patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
The main goal of this trial is to evaluate the usefulness of a new symptom-based scoring system with respect to the identification of patients developing pneumonitis after radiotherapy of breast or lung cancer. The discriminative power of the symptom-based scoring system will be assessed by calculating the area under the ROC curve (AUC). Taking into account that 5% of patients will not qualify for Full Analysis Set, a total of 78 patients should be recruited.
If statistical significance of the AUC is reached, the most-informative (optimal) scoring point to identify radiation pneumonitis will be derived. Sensitivity analyses will be conducted to further investigate the performance of the symptom-based scoring system.
In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with radiation pneumonitis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Background Most patients with small-cell lung cancer (SCLC) receive radiotherapy in combination with chemotherapy as definitive treatment. Also, a considerable number of patients with advanced non-small-cell lung cancer (NSCLC) are treated with radiotherapy with or without concurrent chemotherapy. Radiation pneumonitis is a possible side effect of radiotherapy for lung cancer. Severe pneumonitis was reported to be fatal in approximately 2% of patients. In our centre, the prevalence of symptomatic radiation pneumonitis was 7.6% in patients irradiated for lung cancer. The prevalence of symptomatic radiation pneumonitis in patients with risk factors was 18.8%.
Pneumonitis can occur up to 23 weeks following radiotherapy. Therefore, the symptoms may not be associated with previous radiotherapy, and pneumonitis may be missed. It would be important to identify patients developing radiation pneumonitis and requiring medical treatment more early.
This study aims to develop a symptom-based scoring system that contributes to an earlier detection of radiation pneumonitis requiring medical intervention (grade ≥2) after radiotherapy for lung cancer. This scoring system is a prerequisite for a mobile application, which can be used by the patients at home to rate their symptoms possibly related to pneumonitis.
Patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
Primary endpoint To assess the performance characteristics of the symptom-based scoring system for detection of radiation pneumonitis the receiver operating characteristic (ROC) curve is used to show the connection between sensitivity and specificity for every possible cut-off for the scoring system and to select the optimal scoring point for detection of radiation pneumonitis- The area under the ROC curve (AUC) is calculated to prove the diagnostic ability of the scoring system.
General trial design and duration This is a single-center prospective study, which aims to assess the performance of a new symptom-based score and to identify its optimal scoring point with respect to the detection of patients developing pneumonitis following radiotherapy of breast cancer or lung cancer. The recruitment of all 98 patients (93 patients plus drop-outs) should be completed within 33 months. The treatment period will be 6-7 weeks, and the follow up period 24 weeks. This equals a total running time for the trial of approximately 40 months.
Symptom-Based Scoring System (Paper Version) The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. The patients are asked to state and score their symptoms that are potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to the severity of the symptoms (= symptom scores), and the resulting sum score (patient score) will be used to identify radiation pneumonitis.
During the time of radiotherapy, the patients will complete the paper-based questionnaire directly prior to their appointment with a physician who will perform a physical examination once a week. Following radiotherapy, the patients will be contacted by phone once a week and asked to answer the questions of the questionnaire.
In case of an increase of the total score compared to baseline, patients receive either a follow-up telephone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital. In case of suspected pneumonitis, patients undergo lung function tests. If the suspected diagnosis of pneumonitis is substantiated, patients receive a chest x-ray plus/minus computed tomography. If the diagnosis symptomatic radiation pneumonitis (grade ≥2) has been confirmed, patients receive medical intervention. The vast majority of the patients receive prednisolone, which is considered the mainstay of the treatment for radiation pneumonitis.
The symptom-based sum score is correlated to pneumonitis (yes vs. no). At the end of radiotherapy, patients are asked to complete a questionnaire regarding their satisfaction with the score. In case of a dissatisfaction rate >20%, the score needs modifications before it can be used in future studies. In case of a dissatisfaction rate >40%, it will be considered not useful.
Subgroup Analysis: Symptom-Based Scoring System (Mobile Application) In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding cough, shortness of breath and fever. The symptoms collected by the app will not be evaluated or analyzed. With regard to the app, only its functionality will be tested in this study. The patients will be asked to complete the questionnaire of the app directly after completing the questionnaire of the paper version.
Statistics / Sample size calculation The main goal of this trial is to evaluate the usefulness of a new symptom-based scoring system with respect to the identification of patients developing pneumonitis after radiotherapy for lung cancer. The discriminative power of the symptom-based scoring system will be assessed by calculating the area under the ROC curve (AUC). Assuming a ratio between patients without and with radiation pneumonitis of 3.63, a sample size of 93 patients is required in the full analysis set to yield statistical significance at the significance level of 5% with a power of 90% if the AUC under the alternative hypothesis is in fact at least 0.9. Taking into account that 5% of patients will not qualify for Full Analysis Set, a total of 98 patients should be recruited.
If statistical significance of the AUC is reached, the most-informative (optimal) scoring point to identify radiation pneumonitis will be derived. Sensitivity analyses will be conducted to further investigate the performance of the symptom-based scoring system.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Dirk Rades, MD
- Numéro de téléphone: 45401 0049 451 500
- E-mail: dirk.rades@uksh.de
Sauvegarde des contacts de l'étude
- Nom: Elisa M Werner
- Numéro de téléphone: 45401 0049 451 500
- E-mail: ElisaMarie.Werner@uksh.de
Lieux d'étude
-
-
-
Lubeck Hansestadt, Allemagne, 23562
- Recrutement
- Department of Radiation Oncology, University of Lübeck and University Medical Center Schleswig-Holstein, Ratzeburger Allee 160, 23562 Lübeck, Germany
-
Contact:
- Kirsten Hakelberg, Dr. med.
- Numéro de téléphone: +49-451-500-45410
- E-mail: kirsten.hakelberg@uksh.de
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histologically proven lung cancer
- Indication for radiotherapy
- Risk factors for developing radiation pneumonitis
- Age ≥18 years
- Written informed consent
- Capacity of the patient to contract
Exclusion Criteria:
- Pregnancy, Lactation
- Expected non-compliance
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Participants irradiated for lung cancer
Participants who receive radiotherapy for lung cancer and have risk factors for developing radiation pneumonitis.
Risk factors include mean dose to the ipsilateral lung >13 Gy plus at least one other factor (significant cardiovascular disease, history of heavy smoking (≥40 pack years), previous/concurrent chemotherapy or previous/adjuvant immunotherapy) or mean dose to the ipsilateral lung >20 Gy without other factors.
|
The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy.
In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis.
Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants With Grade ≥2 Radiation Pneumonitis
Délai: 24 weeks following radiotherapy
|
Radiation pneumonitis will been assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
|
24 weeks following radiotherapy
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Dirk Rades, MD, Department of Radiation Oncology, University of Lübeck, Germany
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PARALUC
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .